Navigation Links
iBio Adds New Therapeutic Antibody to Its Pipeline
Date:3/4/2013

NEWARK, Del., March 4, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO)  announced it is proceeding with development of an antibody candidate as a therapeutic against influenza, including highly pathogenic H5N1 strains resistant to drugs such as oseltamivir (marketed as Tamiflu®). This proprietary antibody, which is based upon iBio's iBioLaunch™ technology,  has demonstrated safety and therapeutic efficacy in highly predictive animal models infected with a variety of influenza types, including H5N1.

(Logo:  http://photos.prnewswire.com/prnh/20120419/NY91086LOGO )

The influenza antibody was discovered by scientists at Fraunhofer USA Center for Molecular  Biotechnology (Fraunhofer) and is a part of Bio's successful antibody research collaboration with Fraunhofer.  Prior to the discovery of this influenza antibody product candidate, the collaboration has produced rituximab and palivizumab biosimilar candidates.

"We are pleased to further expand our antibody product candidate pipeline, particularly with an important proprietary candidate," said Robert Kay , Chairman and CEO of iBio. "This development continues our strategy to grant royalty-bearing licenses of iBioLaunch technology to others for development of their products using our platform, as we recently announced with Caliber Biotherapeutics for their anti-cancer monoclonal antibody candidate, while we continue to bring forward our own product candidates for self-development and eventual partnership with others."

About the iBioLaunch™ Platform

The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems may include: success with prot
'/>"/>

SOURCE iBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Comprehensive Global Testing Solutions for Novel Hepatitis C Therapeutics, New Webinar Hosted by Xtalks
2. United Therapeutics Corporation To Announce Fourth Quarter And Annual 2012 Financial Results Before Market Open On Tuesday, February 26, 2013
3. Society for Brain Mapping and Therapeutics endorse President Obamas support for Human Brain Mapping research; nominating him for prestigious Pioneer in Healthcare Policy Award
4. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
5. United Therapeutics Announces Additional $420 Million Share Repurchase Program
6. Juventas Therapeutics Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development
7. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
8. Exon skipping to restore gene expression is promising therapeutic strategy for muscular dystrophy
9. Shield Therapeutics Selects OpenClinica Enterprise
10. Regenetek Research Inc. Launches New Intelligent Software for Therapeutic Stem Cell Trials
11. Cell Therapeutics, Inc.s (CTI) Board of Directors Approves Amendment of Shareholder Rights Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation ... Medtronic, Inc. (NYSE: MDT ) has ... Food and Drug Administration (FDA) for the use ... infusion system (including a newly developed catheter) for ... Injection delivered intravenously to patients with pulmonary arterial ...
(Date:12/24/2014)... and NEW YORK , ... PTBI, PTBIW), a biopharmaceutical company advancing patient care in ... offering of 3,500,000 shares of common stock, and warrants ... common stock, at an offering price of $4.00 per ... per share exercise price of $5.00, are exercisable immediately, ...
(Date:12/24/2014)... 2014  Vermillion, Inc. (Nasdaq:   VRML), a ... today that the Company closed its previously announced ... Jack W. Schuler , Birchview Fund LLC ... million, before offering expenses.  The proceeds will be ... Under the terms of the private ...
(Date:12/24/2014)... 2014   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... shipping products for cells and tissues  ("BioLife" or ... 2015 Annual Meeting of Stockholders on May 4, 2015 ... for the Annual Meeting represents a change of more ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... (NYSE: SGP ) today announced that ... investor relations, effective immediately., In this ... implementing,and continually improving a comprehensive global investor ... formulation and execution of,external and internal investor ...
... September 2008, PLYMOUTH MEETING, Pa., May 27 /Xinhua-PRNewswire-FirstCall/ ... or the ,Company,),today announced that it has received an ... new Propess applicator in China., Prior to today ... induce labor, and is currently distributed via vaginal inserts ...
... Accelerated Community Oncology,Research Network(TM) (ACORN), an ... its expansion of the company,s aggregated ... warehouse. Integrating,patient-reported outcomes (PROs), electronic medical ... systems, garnered from community oncology,practices nationwide ...
Cached Biology Technology:Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations 2BMP Sunstone Receives Import Drug License (IDL) from SFDA 2BMP Sunstone Receives Import Drug License (IDL) from SFDA 3ACORN Expands Oncology Information Portfolio With Comprehensive Data Warehouse 2ACORN Expands Oncology Information Portfolio With Comprehensive Data Warehouse 3
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced ... (GCP) audit to confirm its adherence to current ... accomplishment enables HITLAB to conduct regulated smart device ... principles for patient safety and research quality. ... access, quality, and delivery with innovative technology," said ...
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is ... Facial recognition system measures the overall facial feature ... mouth, and the distance between eyes. Facial recognition ...
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2
... led by CSIRO Climate Adaptation Flagship and University ... evidence that this ,jellyfish joyride, is associated with ... "Dense jellyfish aggregations can be a ... clear picture is now emerging of more severe ...
... Leiden, The Netherlands, June 09, 2009 / b3c newswire ... B.V. and the Netherlands Organisation for Applied Scientific Research ... collaboration agreement to further develop Amarna’s viral gene ... develop novel methods for the manufacture, formulation and testing ...
... 2009 American Society for Microbiology (ASM) Scherago-Rubin Award ... Virginia,s Department of General Services, Division of Consolidated ... bench-level clinical microbiologist. It was established by the ... ASM,s Clinical Microbiology Division, in honor of her ...
Cached Biology News:'Jellyfish joyride' a threat to the oceans 2Amarna Therapeutics B.V. and TNO announce SVac research and development partnership 2Amarna Therapeutics B.V. and TNO announce SVac research and development partnership 3
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
Goat anti-PITPN Class: Antibody Product Group: Miscellaneous Antibody...
COMING SOON: Anti-Mouse CD205 (DEC-205),Clone NLDC-145, mAb...
Anti-MT3-MMP Membrane-Type Metalloproteinase-3; propeptide domain; rabbit host...
Biology Products: